Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Oral anticoagulation and pharmacogenetics: importance in the clinical setting].

Revue medicale suisse - 12 Sept 2007

Benusiglio Patrick R, Desmeules Jules, de Moerloose Philippe, Dayer Pierre

Abstract excerpt

Single nucleotide polymorphisms (SNPs) in genes encoding cytochrome P450 enzyme 2C9 (CYP2C9) and Vitamin K epoxide reductase subunit I (VKORC1) make a significant contribution to the inter-individual variability in the maintenance dose of vitamin K antagonists (warfarin, acenocoumarol, phenprocoumon). Doses requirements in CYP2C9*2 and CYP2C9*3 heterozygotes are reduced by 8-16% and 20-36%, respectively. SNP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mixed Function Oxygenases

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Vitamin K

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 17955831

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Oral anticoagulation and pharmacogenetics: importance in the clinical setting].PMID 17955831Read ↗

[Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy].Semantic proximity Read ↗

Pharmacogenetics aspects of oral anticoagulants therapy.Semantic proximity Read ↗

[The pharmacogenetics of vitamin K antagonists: still a matter for discussion].Semantic proximity Read ↗

Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.Semantic proximity Read ↗

[Pharmacogenomics of vitamin K antagonists].Semantic proximity Read ↗

The future prospects of pharmacogenetics in oral anticoagulation therapySemantic proximity Read ↗

Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.Semantic proximity Read ↗

Role of Warfarin Pharmacogenetic Testing in Clinical PracticeSemantic proximity Read ↗

Pharmacogenetics of warfarin: current status and future challenges.Semantic proximity Read ↗

Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin.Semantic proximity Read ↗

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.